Masimo Corporation

NASDAQ:MASI

Medical - Devices

Healthcare
$179.95 +0.00%

+$0.00 today

Market cap
$9.42B
Beta
1.10
P/E (TTM)
123.1
EPS (TTM)
$1.46
52W Low $125.94High $179.99

Volume 0.00M

Average 1.08M

MASI EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Masimo CorporationNASDAQ: MASI

EBITDA · Q1 FY2026 · quarter ended Apr 2026

EBITDA dips below year-ago levels

Q1 FY2026 EBITDA of $85.5M fell 0.3% year over year, behind the +414.9% change in trailing-twelve-month EBITDA. Sequentially, it fell 10.1% from the prior quarter. Over 3 fiscal years it compounded at -1.0% a year.

Context

  • EBITDA amounted to 22.6% of revenue in FY2025, up 15.0 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of $224.8M (-34.8%) for the fiscal year ending Jan 2027, a slowdown from the +317.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
$85.5M-10.1% QoQ
Last fiscal yearJan 2026
$344.6M+317.1% YoY
LTMApr 2026
$344.5M+414.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.3%-23.6%-23.2 pp
1 year+317.1%-34.8%-351.9 pp
3-year CAGR-1.0%-8.9%-7.9 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
344.6M USD
Year-over-year change
+317.1%
4-year CAGR
+2.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MASI compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +414.9% is the highest of 11, against a peer median of -13.6%.
  • EBITDA amounts to 22.1% of revenue for MASI, versus a peer median of 19.9%.
MASI Competitors
EBITDA for MASI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HSICHenry Schein, Inc.LTM Jun 2026$1.05B USD+8.7%+1.0%7.7%
ATRAptarGroup, Inc.LTM Jun 2026$822.22M USD+1.7%+10.9%20.9%
BAXBaxter International Inc.LTM Jun 2026$750M USD-27.5%—6.5%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$514.7M USD-22.7%—19.9%
MASIMasimo CorporationLTM Apr 2026$344.5M USD+414.9%-1.0%22.1%
MOHMolina Healthcare, Inc.LTM Sep 2026$333M USD-78.1%-10.2%0.8%
STVNStevanato Group S.p.A.LTM Jun 2026€296.36M EUR-4.5%+4.4%24.3%
RGENRepligen CorporationLTM Jun 2026$174.78M USD+55.7%-13.0%22.3%
AVTRAvantor, Inc.LTM Jun 2026$125.3M USD-91.1%-55.0%1.9%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026-$173.24M USD-2.5%—61.7%
ABVXAbivax S.A.FY2025-€300.7M EUR-84.8%——
Peer median (excluding MASI) —-13.6%-4.6%19.9%

Competitors are the stored peer set for MASI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Jan 2026
Revenue1.24B2.04B2.05B2.09B1.53B
Cost of Revenue430.8M977M1.04B1.09B581.7M
Gross Profit808.4M1.06B1B1B945.2M
Gross Margin65.2%52.0%49.0%48.0%61.9%
Research & Development137.2M191.4M175.2M222.8M126.4M
Selling, General & Admin395.4M657.4M664M743.8M506M
Operating Expenses532.6M848.8M867M1.27B632.4M
Depreciation & Amortization35.6M136.1M98.3M103M38.8M
EBITDA310.3M355.2M236.7M(158.7M)344.6M
EBITDA Margin25.0%17.4%11.6%-7.6%22.6%
Operating Income275.8M210M136.5M(266.7M)312.8M
Operating Margin22.3%10.3%6.7%-12.7%20.5%
Interest Income900K1.8M3M4.8M3.4M
Interest Expense300K25.7M50.3M43.6M33.2M
Other Income / Expenses(1.4M)(16.6M)(48.4M)(38.6M)(40.2M)
Income Before Tax274.4M193.4M88.1M(305.3M)272.6M
Pre-Tax Margin22.1%9.5%4.3%-14.6%17.9%
Income Tax Expense44.8M49.9M6.6M(400K)64.9M
Net Income229.6M143.5M81.5M(304.9M)(151.5M)
Net Margin18.5%7.0%4.0%-14.6%-9.9%
EPS (Basic)4.162.681.54(5.72)(2.83)
EPS (Diluted)3.982.601.51(5.72)(2.80)
Weighted Avg Shares55.17M53.6M52.8M53.3M53.6M
Weighted Avg Shares (Diluted)57.68M55.2M54.1M53.3M54.2M

Masimo Corporation

NASDAQ:MASI

Intrinsic Alpha fair value

Locked

Current Price

$179.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.